key: cord-0857909-plxg2zw7
authors: Li, Yuanxin; Sun, Jing; Li, Jingjing; Liu, Kai; Zhang, Hongjie
title: Engineered protein nanodrug as an emerging therapeutic tool
date: 2022-03-07
journal: Nano Res
DOI: 10.1007/s12274-022-4103-2
sha: 533ebf36e0706026156741ab3786cc978f65ab76
doc_id: 857909
cord_uid: plxg2zw7

Functional proteins are the most versatile macromolecules. They can be obtained by extraction from natural sources or by genetic engineering technologies. The outstanding selectivity, specificity, binding activity, and biocompatibility endow engineered proteins with outstanding performance for disease therapy. Nevertheless, their stability is dramatically impaired in blood circulation, hindering clinical translations. Thus, many strategies have been developed to improve the stability, efficacy, bioavailability, and productivity of therapeutic proteins for clinical applications. In this review, we summarize the recent progress in the fabrication and application of therapeutic proteins. We first introduce various strategies for improving therapeutic efficacy via bioengineering and nanoassembly. Furthermore, we highlight their diverse applications as growth factors, nanovaccines, antibody-based drugs, bioimaging molecules, and cytokine receptor antagonists. Finally, a summary and perspective for the future development of therapeutic proteins are presented. [Image: see text]

In the past decades, therapeutic proteins have been increasingly developed for treating certain diseases, such as cancer and immune disorders [1] [2] [3] . Since 2000, hundreds to thousands of patents related to therapeutic proteins have been publicized each year. In addition, the number of relevant publications was expanded from ~ 16,000 in 2000 to ~ 95,000 in 2020. The Food and Drug Administration (FDA) has recently approved over 230 protein-based drug formulations [4] , while a quarter of them have been approved since 2011. Typical therapeutic proteins grouped according to their molecular types including antibodies, enzymes, cytokines, hormones, and interferons, were provided in Table 1 . Therapeutic proteins are superior to small molecule drugs owing to their excellent biocompatibility, high binding selectivity, and specificity. However, the fast enzymatic degradation, renal clearance, and liver metabolism of protein drugs often lead to short half-lives and limited efficacy [5, 6] . As a consequence, the intravenous (IV) or subcutaneous (SC) administration of protein drugs with frequent dosing is needed, which eventually affects patient compliance and therapeutic outcomes [2, 7] . In addition, it is challenging to produce large quantities of therapeutic proteins owing to their limited physical and chemical stability, leading to high costs in the pharmaceutical industry. Therefore, the development of new strategies to improve therapeutic proteins' stability, efficacy, bioavailability, and productivity is urgently needed for clinical applications.

As the physicochemical and enzymatic instability of therapeutic proteins may complicate their nanoformulation process, nanoformulations of therapeutic proteins should be prepared in a moderate condition to avoid loss of bioactivity. Many efforts have been devoted in the past decades to address the issues in developing protein therapeutics nanoformulation [8, 9] . With the advance of recombinant DNA technology, therapeutic proteins can be genetically fused to other proteins commonly used in nanoparticle formulation, such as albumin, elastin-like polypeptide (ELP), ferritin, and lipoprotein [10] [11] [12] [13] . Protein nanoparticles can be produced in mild conditions without using toxic chemicals or organic solvents [11, [14] [15] [16] [17] . Moreover, protein nanoparticles offer the advantages of biocompatibility and biodegradability. Post-translational modification by attaching the protein to polymers is another appealing strategy for long-acting formulation. Such modification is helpful to hide antigenic determinant of a protein and increases the overall size so that the nanodrug will not be cleared out quickly [18] [19] [20] . Additionally, a nanocarrier-mediated delivery platform has been developed for the controlled and sustained release of proteins, thus enabling longacting therapeutics formation. Herein, we summarize recent advances for the nanoformulation and applications of therapeutic proteins. Different strategies for developing therapeutic proteins are presented, including bio-conjugation or genetic recombination, chemical modification, and nanocarrier encapsulation. We further highlight the diverse applications of long-acting protein therapeutics, such as growth factors, nanovacines, antibody-based drugs, fluorescent proteins (FPs), and cytokine receptor

Nanoformulation is an appealing strategy to overcome challenges associated with protein drug therapy, such as short circulatory halflives, poor bioavailability, and high dosage. Various technologies have been proposed and tested for prolonging residence time and improving the therapeutic performance of proteins, including bioconjugation or genetic recombination, chemical modification, and nanocarrier encapsulation.

Protein nanodrugs based on bio-conjugation are designed at the gene level. The genetic engineering leads to the development of recombinant therapeutic proteins that contain functional domains with specific activities and other domains that can decrease immunogenicity or oligomerize to create structure, including albumin, ELP, and antibody Fc fragment. Coupled with the increased protein sizes, the recombinant therapeutic proteins exhibit slow systemic absorption and reduced kidney clearance rates, and can act for a longer time [21] [22] [23] . In contrast to chemical modified proteins, the genetically encoded synthesis endows recombinant therapeutic proteins with high monodispersity.

Human serum albumin (HSA) is a globular protein containing approximately 585 amino acids and is abundant in plasma [17] . HSA exhibits excellent intrinsic properties such as biocompatibility, biodegradability, low immunogenicity, and nontoxicity. Therefore, it is widely utilized to develop the albuminconjugated drug [24] . The genes coding therapeutic protein can be fused to HSA genes by recombinant DNA technology, then expressed in bacterial, yeast, or mammalian systems, yielding the protein-albumin fusions. At present, albumin bioconjugated protein therapeutics, including glucagon-like peptide-1 (GLP-1), human growth hormone (hGH) ( Table 1) , and granulocyte colonystimulating factor protein (G-CSF), are available under preclinical/clinical trials [25] [26] [27] [28] . Notably, the HSA-attached proteins showed a 10 to 1,000 times increase in plasma half-life [26] .

Another approach to extend therapeutic proteins' half-life utilizes a fragmented portion (Fc region) of the immunoglobulin molecule [29] . Bioactive protein motifs can be incorporated into either terminus of the Fc region or inserted into the loop formation via recombinant DNA technology [30, 31] , thus prolonging half-life as the albumin-conjugated one. Furthermore, by taking advantage of the interaction between Fc and the FcRn receptor, the Fc-conjugated proteins bind to FcRn and undergo receptor-mediated endocytosis, which leads to enhanced absorption of therapeutic proteins and increases their effectiveness [32] . A considerable number of Fc-based protein therapeutics are available in the market and under pre-clinical/clinical trials, such as tumor necrosis factor receptor (TNFR) ( Table 1 ) [33] , vascular endothelial growth factor receptor (VEGFR) [34, 35] , and human granulocyte colony-stimulating factor (G-CSF) [36] .

Ferritin is an iron storage protein for preventing cells from metal toxicity. It consists of 24 subunits and has a high molecular weight of 474 kDa [11] . The 24 subunits self-assemble to form ferritin nanoparticles with both external and internal interfaces [37] . The unique structure of ferritin nanoparticles allows the protein cargoes to encapsulate in their inner cavity or display on their outer surface, showing the potential application in the field of therapeutic protein delivery. Deshpande et al. engineered a thermostable protein nanoparticle (tES) by utilizing the ferritins derived from Archaeoglobus fulgidus [38] (Fig. 1(a) ). The genetic fusions of tES monomer and three divergent proteins, including green fluorescent protein (GFPuv), horseradish peroxidase (HRPc), and Renilla luciferase (rLuc), significantly improved expression productivity and stability. More importantly, recombinant proteins internalized by tES showed resistance to thermal, organic, chaotropic, and proteolytic denaturation and were released from the nanoassembly ( Fig. 1(b) ). Jeon et al. demonstrated promising peptide-ferritin nanoparticles by fusing the interleukin-4 receptor (IL-4R)-targeting peptide AP-1, with ferritin-L-chain (FTL) [39] . Due to the multivalent-binding capacity of the AP-1-ferritin nanoparticle, its avidity was increased by about 10 6 fold compared with the AP-1 peptide. Georgiev et al. developed nanovaccines by genetic fusion of HIV-1 antigen (Env) or influenza hemagglutinin antigen (HA) to ferritin [40] . Notably, a dual-antigen nanoparticle was designed via the combined assembly of Env-ferritin and HA-ferritin. The two-component ferritin nanoparticles elicited effective neutralizing antibody responses against the related viruses in guinea pigs. These results provided proof of principle for a general technology for multimeric presentation of protein therapeutics.

ELPs are a family of genetically encoded biopolymers that contain repeats of canonical sequences derived from native elastin [41] . The primary structure of ELPs consists of repetitive pentapeptide units (VPGXG) n , with the X residue being any amino acid except proline. As their similarity to natural elastin, ELPs show exceptional biocompatibility for in vivo applications. One specific property of ELPs is their thermosensitive phase transition behavior, termed lower critical solution temperature (LCST). More specifically, soluble forms of ELPs can be triggered to selfassemble into highly-ordered structures upon heating above the transitional point (T t ) [12] . On the contrary, the thermosensitive ELPs remain hydrated in an aqueous solution below T t . The amino acid sequences of ELPs directly influence T t , and the in vivo aggregation properties can be altered genetically. Consequently, ELPs can be genetically fused to other therapeutic proteins to fabricate thermo-responsive nanodrugs that retain their thermosensitive behavior [42] . Koria et al. demonstrated the fabrication of a fusion protein comprising ELPs and keratinocyte growth factor (KGF) [43] . This fusion protein preserved the characteristic ELPs inverse phase transitioning and self-assembled into nanoparticles at physiological temperatures. These nanoformulation drugs promoted keratinocyte and fibroblast proliferation and re-epithelialization and granulation in the diabetic wound model. Wang et al. engineered a fusion protein termed LSI, with a model mitogenic protein of lacritin fused at the N-terminus of an ELP [44] . This LSI fusion protein underwent thermo-responsive assembly of nanoparticles at physiological temperatures and promoted faster corneal epithelium healing in mice models. More interestingly, the ELP-mediated assembly of LSI is essential for this potent activity. Although ELPs have attracted considerable attention as promising bio-engineering materials, their functional versatility can be further extended to formulate therapeutic proteins. Other protein engineering and design strategies using both ELPs and synthetic polymers are also discussed in the following section.

Apart from the bio-conjugation strategy, the therapeutic protein is often modified with various chemical moieties, including polyethylene glycol (PEG) and lipids. Unlike bio-conjugation, chemical modifications straightforward introduce synthetic polymers to therapeutic proteins through chemical reactions between the polymers and functional groups of protein residues. For example, peginterferon-α 2a was developed via the linkage of PEG moiety at a single site to the interferon-α moiety via a stable amide bond to lysine (Table 1) . Chemical modification masks the protein molecules from enzymatic degradation and contributes to improved bioavailability [45, 46] . As its non-toxic, nonimmunogenic, and hydrophilic characteristics, PEG is the most commonly used polymer for the chemical modification of therapeutic proteins. A variety of PEGylated therapeutic proteins are available in the market, such as interferon-α, G-CSF, and procine-like uricase (Table 1) . Moreover, PEGylated nanoparticle systems are becoming an increasingly important tool for protein and peptide drugs delivery. Steiert et al. reported that the nanoparticles comprised of mPEG-modified lysozymes (LYZ mPEG ) ( Fig. 1(c) ) [47] . The LYZ mPEG nanoassemblies allowed encapsulation of a large hydrophilic payload, and the obtained nanoformulations successfully showed antimicrobial activity against the gram-positive bacteria strain M. Luteus ( Fig. 1(d) ). Ackerman and coworkers reported the development of a novel PEGylated peptide (R321). The R321 peptide could self-assemble into uniform nanoparticles, essentially protecting itself from proteolytic degradation and improving pharmacokinetics (PKs) [48] .

Recently, our laboratory reported an attractive strategy to improve the in vivo stability and efficacy of proteins. A new type of highly charged ELPs manufactured by genetic engineering was presented. After genetically fusing to target proteins, the resulting protein conjugates can electrostatically combine with PEG molecules, forming well-defined nanoassembly [49, 50] . Remarkably, these nanoassemblies offer enhanced stability, bioavailability, and high drug loading capacity, which show great potential for cancer and rheumatoid arthritis (RA) therapy. In addition to PEG molecules, lipids have been widely used to develop protein nanodrugs due to their ability to deliver hydrophilic and hydrophobic payloads and high cell permeability. Recently, Gao's team developed a general method to construct biomimetic nanocarriers comprised of apolipoprotein E (ApoE) and synthetic lipids [51, 52] . The nanocarriers exhibited both blood-brain barrier permeability and Aβ-targeting ability, providing a promising platform for brain drug delivery toward treating Alzheimer's disease (AD). Kim et al. developed a nanoparticle composed of lipid (DOTAP/DOPE) and apolipoprotein 1 (APOA-I) [53] . Protein drugs (cytochrome C) were conjugated with a membrane-permeable sequence (MPS) peptide and non-covalently incorporated into the surface of DOPE/DOTAP nanoparticles. The nanoformulation successfully mediated the targeted delivery and effective penetration of protein drugs into non-small cell lung tumors.

In contrast to directly modifying therapeutic proteins' pharmacokinetic parameters by bio-conjugation and chemical modification, nanomaterials-mediated delivery systems could also be used to produce long-acting therapeutic proteins. Protein delivery systems incorporate the target protein into a matrix or depot and contribute to the slow and sustained release of the protein payload in the circulatory system, thereby extending the half-life and circulation time. Extensive review articles have summarized the advances in synthetic polymer-based delivery systems. Therefore we will focus on nanomaterials from natural or recombinant proteins here. As a drug delivery system, protein nanoparticles have advantages like biodegradability, low toxicity, versatile surface modification, and easy particle size control [6, 38, 47, 49, [51] [52] [53] . Many kinds of natural proteins can be used to fabricate delivery platforms, including albumin, fibroin, gelatin, and collagen.

To enhance the cell-penetrating ability and stability of βgalactosidase, researchers developed a nanoplatform consisting of 30Kc19 protein and HSA [54] . 30Kc19 exhibits anti-apoptotic, cellpenetrating, and enzyme-stabilizing abilities. Thus, 30Kc19-HSA nanoparticles had superior cellular uptake and intracellular stability when compared with HSA nanoparticles. The BSA can also be applied to produce protein delivery micelles. Jiang et al. prepared a PEGylated negatively charged BSA protein, which could load positively charged lysozyme proteins termed Spry1 [55] . Condensation of Spry1 within the PEGylated albumin improved the stability and anticancer efficacy of the Spry1, leading to lowered half-maximal inhibitory concentration (IC 50 ) value against the breast cancer cells and effective growth inhibition of three-dimensional MCF-7 tumor spheroids.

Fibroin is the main protein that exists in silk fibers. Due to its low immunogenicity, biodegradability, mechanical strength, significant productivity, and low cost, fibroin is an attractive material for nanoparticle generation [11, [56] [57] [58] , especially for vehicles of sensitive biologicals such as insulin and growth factors. Kundu et al. reported the fabrication of silk fibroin spherical nanoparticles as depots for VEGF [59] . These nanoparticles can accumulate in the cytosol of murine squamous cell carcinoma cells and support a 3week sustained release of VEGF. Similarly, bone morphogenetic protein-2 (BMP-2) encapsulated by silk fibroin particles was also proved to have elevated stability and bioactivity [60] . In addition, silk protein has been studied as a vector for enzyme transportation, such as glucose oxidase, superoxidase, βglucosidase, L-asparaginase, and Pin1 isomerase [61] . Kim et al. developed cationic lipid-coated fibroin nanoparticles to deliver Pin1 isomerase, a peptidyl-prolyl cis-trans isomerase that plays a critical role in osteoblast differentiation [62] . This fibroin-lipid nanocarrier delivered Pin1 with high efficiency and low cytotoxicity, resulting in the recovery of osteoblast differentiation in Pin1-deficient cells.

Lipoproteins are natural nanoparticles that transport lipid molecules such as cholesterol and fatty acids within the body. Due to its non-immunogenic, biocompatible, biodegradable, and Aβtargeting properties, lipoproteins have become increasingly attractive for drug delivery, especially in treating AD [51] . Huang et al. designed a nanostructure termed monosialotetrahexosylganglioside-modified reconstituted high density lipoprotein (GM1-rHDL) by combining the lipoprotein ApoE and GM1-1,2-dimyristyl-sn-glycero-3-phosphocholine (DMPC) liposome [63] . The GM1-rHDL as a flexible nanoplatform showed an average particle size of about 25 nm and was able to load neuroprotective peptide αNAP. αNAP-GM1-rHDL significantly reduced Aβ deposition and rescued the memory loss in the AD mice model, which was more effective than both αNAP solution and GM1-rHDL alone.

Similarly, this team further developed another nanoplatform (RAP-RL) constituted with GM1-DMPC, ApoE, and an antagonist peptide (RAP) of the receptor for advanced glycation end-products (RAGE) (Fig. 2(a) ) [64] . The RAP-RL displayed a nanodisc structure where the RAP peptides are often incorporated into the surface (Fig. 2(a) ). The RAP-RL efficiently reversed the transfer of claudin-5 from the cell membrane to the cytoplasm induced by Aβ treatment and alleviated Aβ-induced tight-junction impairment ( Fig. 2(b) ). The integrity and function of neurovascular units in AD model mice were regained, and cognitive abilities were improved through the synergistic effect of RAP-RL. The nanocarriers prepared here with recombinant lipoprotein and commercially available synthetic lipids have good biocompatibility and are more easily scalable and reproducible. On this basis, these works provide a promising nanoplatform for AD treatment by delivering protein drugs through lipoprotein nanoparticles.

Wang et al. exploited glutaraldehyde (GA) crosslinked gelatin nanomaterials that can deliver multiple growth factors (basic fibroblast growth factor (bFGF) and BMP-2) in a controlled manner [65] . Notably, the modulation of the growth factor's release kinetics was realized by changing the degree of crosslinking. It provides a novel and convenient dual delivery approach for the slow and sustained release of therapeutic proteins. The photoresponsive protein termed CarH C [66] generated a stimuli-responsive "smart" hydrogel using genetically encoded SpyTag-SpyCatcher chemistry under mild physiological conditions [67] . The CarH C hydrogel was able to encapsulate and release the fluorescent protein of mCherry in a light-dependent manner (Fig. 2(c) ). The release of mCherry-CarH C in this system can be readily controlled by adjusting the light irradiation time ( Fig. 2(d) ). This study presents a versatile strategy for designing stimuli-responsive materials that allow for dynamically tunable drug administration.

The nanoformulations of therapeutic proteins help maintain drug efficacy and stability over time and thus have shown great potential in different aspects, including bioimaging, diagnosis, disease intervention, and therapy.

A growth factor is a kind of multi-effect peptide that regulates cell growth and other cell functions through binding to specific, highly compatible cell membrane receptors. Growth factors generally show a short retention time, usually a few hours in vivo [4] , which needs to be extended to achieve the desired efficacy. Bessa et al. created the nanoparticles by thermoresponsive self-assembly of elastin-like polymer (VPAVG) 220 for delivery of BMPs [68] . These BMPs could be efficiently encapsulated and released in a sustained way for 14 days. The activity of BMPs was retained, as demonstrated by the induction of alkaline phosphatase activity and osteogenic mineralization in C2Cl2 cells. In addition to both growth factors alone, the combined release of BMP-2 and BMP-14 exhibited high bioactivity. This work potentially paves the way for developing multifunctional carriers for the delivery of growth factors.

Furthermore, growth factors can be displayed on the surface of nanoparticles by fusion with the protein carrier. By genetically fusing the epidermal growth factor (EGF) to the C-terminus of a bacteriophage capsid protein Qβ, Finn and coworkers developed virus-based nanoparticles displaying 5 to 12 copies of EGF on their exterior surface [69] . Additionally, the nanoparticle-displayed EGF promoted auto-phosphorylation of the EGF receptor and apoptosis of A431 cells, demonstrating the bioactivity of nanoparticle-displayed EGF. Interestingly, the EGF-displayed nanoparticles could be valuable carriers for the targeted delivery of therapeutic agents [70] .

The successful applications of nanotechnology hold great promise for the development of nanovaccines. Compared with the traditional vaccines, nanovaccine offers several advantages, including high antigen-loading efficiency, enhanced efficacy, and stability [71] . Here, we introduce several kinds of nanovaccines which have been developed for the prevention of infectious disease or cancer therapy. The self-assembled peptide nanoparticles [72] were used to produce a severe acute respiratory syndrome (SARS) nanovaccine [73] , which repetitively displays the SARS B-cell epitope HRC1 at the exterior surface. Immunization experiments revealed the infection-inhibition activity of these peptide nanoparticles. This work represents a promising platform for nanovaccine design, particularly for diseases characterized by neutralizing epitopes [14] . Nabel and coworkers designed a selfassembled nanoparticle vaccine by genetically fusing viral hemagglutinin to the N-terminus of ferritin [74] , which improves the efficacy and breadth of influenza virus immunity compared to commercially available influenza vaccines [74] . Marcandalli et al. designed a protein nanoparticle vaccine for a respiratory syncytial virus (RSV) via in vitro assembly of computationally designed recombinant proteins [75] . The RSV surface F glycoprotein termed DS-Cav1 was fused to the computationally designed protein I53-50A, generating DS-Cav1-I53-50A (Fig. 3(a) ). Afterward, the highly ordered nanoparticle immunogens were formed, driven by the assembly of DS-Cav1-I53-50A with another pentameric protein, I53-50B (Fig. 3(a) ). As shown in Fig. 3(b) , the nanovaccine induced approximately 10-fold higher neutralizing antibody responses than the trimeric DS-Cav1. This work offers new opportunities for structure-based vaccine design.

Through genetic recombination, it is possible to effectively integrate two or more antigenic proteins to improve the potency and breadth of vaccines. Therefore, nanoparticle immunogens codisplayed four kinds of haemagglutinins have been fabricated [76] . The nanoparticles induced broadly protective antibody responses against different heterologous viruses, even in the presence of antigenic mismatches in the hypervariable head domain. To improve the protective breadth and lower the off-target risk of influenza vaccine, Deng et al. fabricated bilayer protein nanoparticles via desolvating tetrameric influenza matrix protein 2 ectodomains (M2e) into protein nanoparticle cores and encapsulating these cores by crosslinking partial domains of HAs (Fig. 3(c) ) [77] . As shown in Fig. 3(d) , these protein nanoparticles elicited solid and broad immune activities to various HA antigens. In addition, self-assembling virus-like particles have been developed as valuable tools for cancer immunotherapy [78, 79] . All these findings suggested the great potential of self-assemble protein nanoplatforms for clinical applications.

Therapeutic antibodies, especially monoclonal antibodies (mAbs), as the most abundant and the fastest-growing groups of protein therapeutics, are being gradually improved for efficacy, safety and cost. Here, new engineered antibody therapeutic formats are introduced, including nanobides (Nbs), antibody fragement nanoasemblies and antibody-drug conjugates (ADCs). By engineering antibody variable (Fv) regions, many antibody fragments were achieved, such as single-chain variable fragments (scFv) and Nbs. Unlike traditional full-length antibodies, these antibody fragments are small (~ 15 kDa for Nbs), highly soluble, lowly susceptible to steric hindrances and amenable to rapid and low-cost microbial production. Recently, a viarety of Nbs have been in preclinical/clinical development for diseases such as brain cancer, inflammation disorder and viral infection [80, 81] . Shi and coworkers discovered an extensive repertoire of robust neutralizing Nbs to SARS-CoV2 [82] . Moreover, the homotrimeric, multivalent Nb constructs (IC 50 as low as 0.058 ng/mL) were fabricated using tandem-repeat strategy and produced in a large scale from E. coli. These Nbs provided costeffective and efficacious therapeutics to combat the COVID-19 pandemic.

Another way to generate high-valency antibody constructs is to use polypeptide-mediated nanoassembly of antibody fragments [83] . Antibody fragments assembled through fusion with oligomerization domains, including ELPs, collagen-like polypeptides, albumin, transmembrane proteins, etc. Compared with multivalent constructs generated by consecutive conjugation, the polypeptide-mediated nanoassembly may address the instability of tandem-repeated antibody fragments. Alam et al. described a SpyCatcher/SpyTag based platform to construct trivalent anti-human epidermal growth factor receptor 3 (HER3) scFv [84] . As shown in Fig. 4(a) , three anti-HER3 scFv fused SpyCatchers were ligated to one synthetic Tri-SpyTag peptide, generating a Tri-scFv construct. The HER3 affinity of the Tri-scFv was 12 times higher than that of the monovalent control. This study presents a promising platform for antibody assembly and multivalency.

Antibody-drug conjugates (ADCs) consist of recombinant mAbs that covalently bind to cytotoxic small-molecule drugs via synthetic linkers (Fig. 4(b) ), combining the antitumor activities of chemotherapeutic agents with the high selectivity and preferred pharmacokinetics of mAbs [85] . Although only two ADCs, brentuximab vedotin and trastuzumab emtansine, have been approved by FDA, there are more than 60 ADCs in clinical trials. Major future directions for ADCs are to explore the best target antigens, appropriate chemotherapeutic agents as well as optimized linkers. Specifically, the incorporation of pH-sensitive [86] or photo-sensitive [87] linkers into ADCs allows rapid and controllable drug detachment, providing new opportunities for reducing toxicities to normal tissues while improving therapeutic efficacy.

Fluorescent proteins have been widely used as markers for imaging cells and tissues treated by gene transfection, especially for non-invasive and quantitative visualization of tumor growth and metastasis in vivo [88] . However, limited transfection efficiency and lack of targeting ability restrict their clinical application. The development of FPs or derived materials, which can be directly applied for bio-imaging, represents a promising solution to these issues. Guan et al. reported an FP-based nanoparticle developed through the genetic fusion of the cell-penetrating peptides (CPPs) and enhanced green fluorescent protein (EGFP) [89] . The EGFP nanoparticle displayed high stability in mouse plasma and preferentially accumulated in the tumor after tail vein administration. As the GFPs suffer from the short tissuepenetration depth and high autofluorescence background, advanced near-infrared (NIR) FPs with excitation and emission maxima inside the NIR window have been developed [90] . Some genetically engineered NIR FPs show adequate high brightness, photostability, and signal-to-background ratio, such as mIFP [91] . Our group developed the mIFP-based nanoassemblies with NIR emission and outstanding photostability by electrostatic complexation between positively charged mIFP conjugates and anionic carboxylate-terminated PEG-COO − chains (Figs. 5(a)-5(c)) [49] . Remarkably, stable and long-time imaging of the tumor sites, including tumor xenografts and metastatic tumor nodules (Fig. 5(d) ), was achieved through a single intravenous injection, overcoming the limitations of FP bioimaging that relies on gene transfection and rapid fluorescence decay. Inspired by this strategy, many other protein-based nanomaterials were successfully developed and applied to treat various diseases [50, [92] [93] [94] [95] .

IL-1 receptor antagonists (IL-1Ra) modulate the IL-1 receptor signaling pathway, antagonize IL-1-induced secretion of inflammation mediators, downregulate the activity of matrix metalloproteinases (MMPs) [96] , and are therefore regarded as an effective tool for blocking IL-1-induced inflammatory diseases. Particularly, recombinant IL-1Ra has been approved for RA (Table 1 ) [97] . However, daily injection of a high dose (100 mg daily) is usually required to maintain a therapeutic concentration of IL-1Ra due to its fast degradation in serum. As a consequence, researchers have exploited IL-1Ra depots that provide sustained drug release and desired bioefficacy. Shamji et al. genetically synthesized a fusion protein combining IL-1Ra and thermalresponsive ELPs [98] . The resulting fusion proteins aggregated through the thermal phase-transitioning behaviors of the ELP domains, thus forming an IL-1Ra-containing drug depot after orthotopic injection in vivo. Although the in vitro bioactivity of ELP-IL-1Ra is lower than that of the free IL-1Ra, ELP-IL-1Ra might provide a longer persistence time in the joint. Liu and coworkers developed and characterized supramolecular IL1-Ra nanoformulations with significantly improved efficiency for RA treatment (Fig. 6) [50] . As shown in Fig. 6(a) , IL-1Ra was firstly fused to positively charged ELPs, then encapsulated into supramolecular assemblies via electrostatic complexation with PEG or chondroitin sulfate (CS), generating morphologically welldefined IL-1Ra nanoformulations. Significantly, these nanoformulations possessed a typical controlled release behavior ( Fig. 6(b) ) and offered strikingly increased half-life of 30 h and bioavailability of 7-times higher than pristine IL-1Ra (Figs. 6(c) and 6(d)). In the collagen-induced RA rat models, IL-1Ra nanoformulations showed extraordinary long-term antiinflammatory effects and robust bioefficacy for RA therapy Fig. 6(e) ), with smooth and intact morphology of the joints compared to destructions and damages of ankles in the PBS and IL-1Ra groups. The bioefficacy could maintain up to 14 days in RA rat models. This noncovalent assembly strategy via engineered chimeric protein and chemical modification might be adapted for other therapeutics to form long-acting formulations.

When administrated in vivo, nanoparticles inevitably contact with biomolecules in the physiological fluid, generating a "biomolecule corona" on the surface of nanoparticles [99] . This process dramatically influences the biological properties of the nanoparticles, including blood circulation lifetime, cellular uptake rate, bioavailability, and toxicity. Therefore, one way to improve nanoparticles' in vivo properties and achieve targeted drug delivery is to decorate the nanoparticles' surface. Albumin or albumin-binding moieties have been modified on the nanoparticle surface to achieve a better serum half-life. Azizi et al. developed albumin-coated silver nanoparticles (ASNPs) that showed high anti-cancerous activity in vivo [100] , indicating that ASNPs could be a good candidate for nanomedicine. Chilkoti and coworkers reported an albumin-binding domain (ABD) conjugate of chemotherapeutic of doxorubicin (ABD-Dox), which showed significantly prolonged half-life than free Dox [101] . The 47-aa ABD was biosynthesized as an ELP-ABD fusion from microbial expression system, representing a promising candidate for nanomaterial modification. Wurm and coworkers found that clusterin (also known as apolipoprotein J) reduced non-specific cellular uptake of polymer-coated polystyrene nanoparticles [102] . In addition, protein-mediated nanoparticle surface modification is important for direct targeting to specific cells or tissues. Certain apolipoproteins are helpful in nanoparticles' transport over the blood-brain barrier (BBB) [51, 63, 64, 103] . Recently, Chen et al. achieved the first NIR-II photoacoustic imaging-guided therapy nanoplatform of RA [104] . Polymer nanoparticles for NIR-II photoacoustic molecular imaging were conjugated with therapeutic mAb tocilizumab (TCZ) with RA therapeutic and targeting functions to develop mAb-coated TCZ-PNPs that confer RA-targeted imaging and therapy.

Therapeutic proteins are essential tools for the effective therapy of various diseases, and in certain situations, they are irreplaceable. We have reviewed the progress of protein-based nanodrugs over the past decades. Strategies for extending the half-life and stability of therapeutic proteins are highlighted, including bio-conjugation via genetic engineering, chemical modification, and nanosystem delivery. Moreover, we have summarized the achievements in exploring functional nanoformulations of proteins for disease diagnosis and treatment. Therapeutic proteins are endowed with improved stability, biocompatibility bioavailability, and bioefficacy by nanoformulations, significantly reducing the treatment costs and improving patient compliance.

Despite all the advances made, challenges remain in the development of protein nanomedicines. For example, the efficacy reproducibility of protein nanomedicines needs to be addressed. In this context, the development of highly robust and facile synthetic approaches is needed. Especially, the physical and chemical properties of engineered protein should be considered for nanoformulation. Computational-aided methods can be applied extensively to select the optimal protection sites in the nanoformulation process. In addition, new synthetic strategies for therapeutic proteins are needed to realize large-scale and low-cost production. In this context, the development of novel synthetic biology tools that can facilitate the expression systems, including bacterial, yeast, or mammalian cells, can be an efficient choice to pave the way. Furthermore, novel nanoplatforms that enable the integration of proteins and small molecule drugs might be a promising way to establish a new paradigm for collaborative therapy.

Protein therapeutics-lessons learned and a view of the future

Engineering of therapeutic proteins

Protein nanotherapeutics as an emerging modality for cancer therapy

Database of FDA-approved peptide and protein therapeutics

Strategies to improve plasma half life time of peptide and protein drugs

Current strategies in extending half-lives of therapeutic proteins

Recent advancements in non-invasive formulations for protein drug delivery

Drug targeting via platelet membranecoated nanoparticles

A Colorimetric test to differentiate patients infected with influenza from COVID-19

Protein corona: A new approach for nanomedicine design

Protein-based nanoparticles as drug delivery systems

Protein-based artificial nanosystems in cancer therapy

Recombinant protein materials for bioengineering and nanomedicine

Peptide gels for controlled release of proteins

Developing proteinbased nanoparticles as versatile delivery systems for cancer therapy and imaging

Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy

Self-assembled non-covalent protein-drug nanoparticles: An emerging delivery platform for anti

Recent advance in polymer based microspheric systems for controlled protein and peptide delivery

Nano based drug delivery systems: Recent developments and future prospects

N-glycosylation increases the circulatory half-life of human growth hormone

Fusion proteins for half-life extension of biologics as a strategy to make biobetters

Enhancing exposure of protein therapeutics

Polymer-drug conjugate therapeutics: Advances, insights and prospects

Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy

Half-life extended biotherapeutics

Albumin and its application in drug delivery

Spiegelstein, O. Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: Results of a phase 3 trial

Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice

Fc-based cytokines: Prospects for engineering superior therapeutics

Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery

Pharmacokinetics of monoclonal antibodies and Fcfusion proteins

Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis

Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial

Fc-fusion proteins and FcRn: Structural insights for longer-lasting and more effective therapeutics

Granulocyte colony-stimulating factor (GCSF) fused with Fc domain produced from E. coli is less effective than

Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development

Thermostable exoshells fold and stabilize recombinant proteins

Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity

Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens

Elastin-based materials

Elastin-like polypeptides: Biomedical applications of tunable biopolymers

Self-assembling elastin-like peptides growth factor chimeric nanoparticles for the treatment of chronic wounds

Lacritin-mediated regeneration of the corneal epithelia by protein polymer nanoparticles

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates

Protein-polymer conjugation-moving beyond PEGylation

Protein-based nanoparticles for the delivery of enzymes with antibacterial activity

Novel peptide nanoparticlebiased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness

Engineered near-infrared fluorescent protein assemblies for robust bioimaging and therapeutic applications

Significantly improving the bioefficacy for rheumatoid arthritis with supramolecular nanoformulations

Biomimetic ApoEreconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery

Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer' s disease by accelerating the clearance of amyloid-beta

The targeted intracellular delivery of cytochrome C protein to tumors using lipidapolipoprotein nanoparticles

protein and human serum albumin nanoparticles

PEGylated albumin-based polyion complex micelles for protein delivery

Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy

Crosslinked fibroin nanoparticles: Investigations on biostability, cytotoxicity, and cellular internalization. Pharmaceuticals (Basel) 2020, 13

Colloidal stability of silk fibroin nanoparticles coated with cationic polymer for effective drug delivery

Silk fibroin nanoparticles for cellular uptake and control release

Silk fibroin microparticles as carriers for delivery of human recombinant bone morphogenetic protein-2: In vitro and in vivo bioactivity

Bioconjugation of silk fibroin nanoparticles with enzyme and peptide and their characterization

Direct delivery of recombinant Pin1 protein rescued osteoblast differentiation of Pin1-deficient cells

GM1-modified lipoprotein-like nanoparticle: Multifunctional nanoplatform for the combination therapy of Alzheimer' s disease

Multifunctional nanostructure RAP-RL rescues Alzheimer' s cognitive deficits through remodeling the neurovascular unit

Combined delivery of BMP-2 and bFGF from nanostructured colloidal gelatin gels and its effect on bone regeneration in vivo

Elías-Arnanz, M. Light-dependent gene regulation by a coenzyme B 12 -based photoreceptor

B 12 -dependent photoresponsive protein hydrogels for controlled stem cell/protein release

Thermoresponsive self-assembled elastin-based nanoparticles for delivery of BMPs

Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor

Targeting of EGF-displayed protein nanoparticles with anticancer drugs

Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection

Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles

Peptide nanoparticles as novel immunogens: Design and analysis of a prototypic severe acute respiratory syndrome vaccine

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus

Quadrivalent influenza nanoparticle vaccines induce broad protection

Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

Nanoparticle adjuvant sensing by TLR7 enhances CD8 + T cellmediated protection from Listeria monocytogenes infection

The therapeutic potential of nanobodies

Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

Live long and active: Polypeptidemediated assembly of antibody variable fragments

A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system

Strategies and challenges for the next generation of antibody-drug conjugates

Milatuzumab-SN-38 conjugates for the treatment of CD74 + cancers

Photosensitizer antibody-drug conjugates: Past, present, and future

The multiple uses of fluorescent proteins to visualize cancer in vivo

A tumortargeting protein nanoparticle based on Tat peptide and enhanced green fluorescent protein

A set of monomeric near-infrared fluorescent proteins for multicolor imaging across scales

A naturally-monomeric infrared fluorescent protein for protein labeling in vivo

An engineered protein adhesive with properties of tissue integration and controlled release for efficient cartilage repair

Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment

Engineered protein photo-thermal hydrogels for outstanding in situ tongue cancer therapy

An artificial phase-transitional underwater bioglue with robust and switchable adhesion performance

Role of interleukin-1 and tumor necrosis factor α in matrix degradation of human osteoarthritic cartilage

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: Sustained release of a local antiinflammatory therapeutic

The Crown and the Scepter: Roles of the protein corona in nanomedicine

Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line

Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin

Protein adsorption is required for stealth effect of poly(ethylene glycol)-and poly(phosphoester)-coated nanocarriers

Brain-targeted drug delivery by manipulating protein corona functions

Tocilizumabconjugated polymer nanoparticles for NIR-II photoacousticimaging-guided therapy of rheumatoid arthritis